bivalent bnt162b2 Search Results


bnt162b2 bivalent mrna vaccine  (BioNTech)
90
BioNTech bnt162b2 bivalent mrna vaccine
Bnt162b2 Bivalent Mrna Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pm36804967-5-31-35
Average 90 stars, based on 1 article reviews
bnt162b2 bivalent mrna vaccine - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
bivalent bnt162b2  (Pfizer Inc)
86
Pfizer Inc bivalent bnt162b2
Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
Bivalent Bnt162b2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2+%EA%B2%B0%EA%B3%BC%EB%A5%BC+%EB%95%8C+%EB%B3%BC+%EC%A2%85+%ED%95%A9%ED%95%B4+%ED%98%88%EC%95%A1%EA%B2%80%EC%82%AC/pmc13154980-26-8-11
Average 86 stars, based on 1 article reviews
bivalent bnt162b2 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
bnt162b5 bivalent (wt/omi ba.2)  (BioNTech)
90
BioNTech bnt162b5 bivalent (wt/omi ba.2)
Selected mRNA vaccines against viral pathogens posted on the clinical trial lists by the National Library of Medicine, NIH, USA (accessed date: October 17, 2022).
Bnt162b5 Bivalent (Wt/Omi Ba.2), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bivalent+bnt162b2/bnt162b5+bivalent++wt+omi+ba+2+/pmc09837160-9-1-6
Average 90 stars, based on 1 article reviews
bnt162b5 bivalent (wt/omi ba.2) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

Journal: Human Vaccines & Immunotherapeutics

Article Title: NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

doi: 10.1080/21645515.2026.2638022

Figure Lengend Snippet: Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

Article Snippet: In Singapore, the bivalent mRNA-1273 (ancestral/BA.1, Moderna) and bivalent BNT162b2 (ancestral/BA.4/5, Pfizer) vaccines were added to the National Vaccination Programme from October 2022 and were recommended in place of the original monovalent vaccines.

Techniques: Comparison, Infection

Selected mRNA vaccines against viral pathogens posted on the clinical trial lists by the National Library of Medicine, NIH, USA (accessed date: October 17, 2022).

Journal: Biomedical Journal

Article Title: Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2

doi: 10.1016/j.bj.2023.01.002

Figure Lengend Snippet: Selected mRNA vaccines against viral pathogens posted on the clinical trial lists by the National Library of Medicine, NIH, USA (accessed date: October 17, 2022).

Article Snippet: , BNT162b5 Bivalent (WT/OMI BA.2) , BioNTech SE , Phase 2|Phase 3 , NCT05472038 , Wildtype and Omicron BA.2.

Techniques: Vaccines, Variant Assay, Virus, Infection